Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Work In Process (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Work In Process for 4 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Work In Process rose 25.36% to $4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.4 million, a 25.36% increase, with the full-year FY2024 number at $2.9 million, up 46.67% from a year prior.
  • Work In Process was $4.4 million for Q3 2025 at Gyre Therapeutics, up from $4.2 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $4.4 million in Q3 2025 to a low of $2.0 million in Q4 2023.
  • A 4-year average of $3.3 million and a median of $3.4 million in 2025 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: crashed 45.54% in 2023, then surged 46.67% in 2024.
  • Gyre Therapeutics' Work In Process stood at $3.7 million in 2022, then plummeted by 45.54% to $2.0 million in 2023, then soared by 46.67% to $2.9 million in 2024, then skyrocketed by 51.38% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Work In Process are $4.4 million (Q3 2025), $4.2 million (Q2 2025), and $3.4 million (Q1 2025).